Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular-Growth
This index fund/ETF has a beta of nan%, and an expense ratio of 1.21%, giving it a 0.0 star rating, based on the principle that lower values of |1-beta| and expense ratio result in higher ratings.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
Returns
8 Oct 2026 நிலவரப்படி
Portfolio
31 Aug 2026 நிலவரப்படி
Market-cap பிரிவு
துறை ஒதுக்கீடு
Holdings (31)
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Laurus Labs Ltd. | 11.23% | ₹5.7 Cr | 29,782 |
| Lupin Ltd. | 8.01% | ₹4.07 Cr | 18,589 |
| Aurobindo Pharma Ltd. | 7.16% | ₹3.64 Cr | 21,187 |
| Fortis Healthcare Ltd. | 7.12% | ₹3.62 Cr | 39,889 |
| Glenmark Pharmaceuticals Ltd. | 5.63% | ₹2.86 Cr | 11,525 |
| Alkem Laboratories Ltd. | 4.70% | ₹2.39 Cr | 4,479 |
| Biocon Ltd. | 4.43% | ₹2.25 Cr | 54,611 |
| Ipca Laboratories Ltd. | 4.13% | ₹2.1 Cr | 10,633 |
| Mankind Pharma Ltd. | 4.11% | ₹2.09 Cr | 8,637 |
| Gland Pharma Ltd. | 3.46% | ₹1.76 Cr | 6,099 |
Fund விவரங்கள்
Return that corresponds to the returns of the Nifty MidSmall Healthcare Total Return Index, subject to tracking error. Long term capital growth.
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
Exit load of 1%, if redeemed within 15 days.